First-ever Huntington staging system may jump-start drug development for early-stage diseaseJune 30, 2022Rare DiseasesNeuromuscular Disorders
FDA unveils 5-year plan for ALS and other neurodegenerative diseasesJune 29, 2022Rare DiseasesNeuromuscular DisordersNeurodevelopmental Disorders
FDA expands indication for spinal muscular atrophy drugMay 31, 2022Rare DiseasesPediatricsNeuromuscular Disorders
Nanoparticle shows promise for ALSApril 6, 2022Rare DiseasesNeuromuscular DisordersMovement Disorders
FDA advisory panel rejects new ALS drugMarch 31, 2022Rare DiseasesNeuromuscular DisordersMovement Disorders
Tremors and memory loss precede Parkinson’s in diverse populationMarch 7, 2022Parkinson's DiseaseNeuromuscular DisordersMovement Disorders
Long COVID patients may develop nerve damage: StudyMarch 4, 2022COVID-19 UpdatesNeuromuscular DisordersLong COVID
Newborn Screening for Spinal Muscular Atrophy in the United StatesDecember 22, 2021Neuromuscular Disorders
A safer way to use Botox to treat challenging dystonia type?October 7, 2021Movement DisordersNeuromuscular Disorders
Investigative botulinum toxin formulation shows prolonged effectSeptember 23, 2021Movement DisordersNeuromuscular Disorders
